PENSACOLA, FL, July 17, 2025 – Ametris (formerly ActiGraph), a global digital health solutions provider transforming real-world patient data into validated clinical evidence, announced a new strategic partnership today with Modality.AI, a pioneer in AI-powered audio and visual biomarker technology for the assessment of neurological and psychiatric conditions. This strategic partnership provides a robust set of digital assessments to help researchers better understand disease progression and enhance clinical trials in a historically challenging area of drug development.
The Modality.AI solution enables clinical researchers to conduct objective, self-guided clinical assessments without the need for additional software or apps. Modality.AI’s platform engages patients in automated conversations with a virtual guide “Tina” to generate real-time, clinically meaningful assessments critical for the evaluation of complex neurological conditions. The platform is currently in use by leading pharmaceutical and biotech sponsors and clinical institutions around the world and has been featured in over 120 publications and 45 clinical studies.
This collaboration brings together Modality.AI’s HIPAA-, GDPR- and FDA CFR Title 21-compliant multimodal assessment platform with Ametris’ end-to-end digital trial software and data collection platform, enabling the remote collection of clinically validated audio and visual biomarkers alongside real-world measures of physical function, sleep, and vital signs for a holistic view of participant function.
This new joint offering enhances clinical trials targeting progressive neuromuscular and movement disorders, such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease, by allowing researchers to collect complementary data of continuous, passive measures of real-world function as well as active assessments of language and speech patterns, fine motor control, and cognitive function.
“We are thrilled to welcome Modality.AI to our Accelerant™ partnership program,” said Christine Guo, Chief Scientific Officer at Ametris. “By combining Ametris’ proven expertise in real-world functional and physiological monitoring with Modality.AI’s advanced audio-visual assessment platform, we’re addressing the challenges with poor outcome measurements in clinical trials in neurology and mental health, areas where more frequent, remote measures are critical to advancing our understanding of disease progression and developing new treatments.”
“The heterogeneity of neurodegenerative and neuropsychiatric conditions calls for comprehensive albeit sensitive and clinically meaningful measures which tell the complete story of disease progression and the effect of investigational therapies. The joint product offering of Ametris and Modality.AI provides a digital biomarker solution addressing one of the industry’s most burning questions: Is our therapy demonstrating measurable efficacy?” shared David Suendermann-Oeft, founder and CEO of Modality.AI.
This strategic partnership further expands the digital measures available to researchers and drug developers, enabling more frequent and sensitive assessments to better characterize participants’ symptoms and more accurately evaluate treatment effects.
About Ametris
Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support to simplify every phase of a clinical trial—from study design to submission. Backed by two decades of experience and a collaborative approach, Ametris empowers research teams to run smarter trials, reduce patient burden, and accelerate therapeutic innovation.
About Modality.AI
Modality’s audiovisual AI platform measures speech, facial, and behavioral patterns of participants in clinical research. These patterns can indicate the status of complex neurological conditions like ALS, Parkinson's disease and schizophrenia. Research participants are assisted by Tina, a virtual clinical guide, and use their own computer, smartphone, or tablet in the comfort and privacy of their home. Modality’s AI platform processes the audio and video and derives objective measurements used by researchers to understand the course of disease and therapeutic treatment effects. Modality.AI was founded by AI/ML experts who collaborate with leading research institutions and biopharma companies developing new therapeutics.